)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
XVIVO Perfusion (XVIVO) investor relations material
XVIVO Perfusion Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary11 Jul, 2025
Executive summary
Q2 2025 net sales were SEK 178 million, down 15% year-over-year, with organic growth at -11% and a weak US dollar further impacting results.
Strong growth in US lung sales to clinics (+26%), European liver sales (+32%), and US kidney sales (+47%), while Thoracic and Services segments declined.
Clinical trial results for heart and liver products showed strong efficacy and cost-effectiveness, supporting future commercialization.
Strategic investments in field force, R&D, and inventory are driving growth in targeted segments and supporting future demand.
Regulatory milestones achieved, including FDA approvals for key clinical studies and progress in Europe and Canada.
Financial highlights
Q2 net sales: SEK 178 million (down from SEK 210 million in Q2 2024); H1 net sales flat at SEK 396 million.
Gross margin stable at 74% in Q2 and H1; adjusted EBITDA margin at 13% for Q2, 18% for H1.
Q2 operating income (EBIT): SEK 7 million (down from SEK 33 million); H1 EBIT: SEK 34 million.
SEK 9 million positive operating cash flow in Q2; cash position at SEK 323 million at period end.
Investments totaled SEK 72 million in Q2, mainly for US clinical trials, R&D, and inventory.
Outlook and guidance
Cost restructuring prioritizes investments in field force and customer-facing roles to drive growth.
Heart product launches prepared for Europe, Australia/NZ, and Canada, pending regulatory approvals.
US regulatory and clinical activities for heart and liver ongoing; first US liver trial patient targeted for H2 2025.
Main growth drivers expected to be EVLP in the US and liver/kidney in Europe, with additional growth from heart post-approval.
Long-term outlook remains positive, with demand for transplants far exceeding supply and machine perfusion expected to drive future growth.
Assess the impact of destocking on lung sales.
When is the expected Europe heart tech launch?
Explain the strategic inventory build-up.
How will new XPS accounts offset destocking?
Describe the heart launch ramp-up in Europe.
How will NRP services impact US lung transplants?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next XVIVO Perfusion earnings date
Q3 202523 Oct, 2025
Next XVIVO Perfusion earnings date
Q3 202523 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Xvivo Perfusion AB, a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company's primary product line are the xVivo Perflex System and the xVivo S System that combine perfusion technology with a robust cryopreservation solution to maintain viability of cells outside the body. The xVivo Perflex System is used for functional organ preservation. The company is based in Gothenburg, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage